Zimmer Biomet saw just under $2.1 billion in first-quarter sales, according to financial results posted April 28.
Seven things to know:
1. Net sales of $2.08 billion represent a 9.3% year-over-year increase.
2. Knee and hip sales saw year-over-year revenue gains. Knee sales were $828.6 million, a 4.5% increase. Hips saw $524.1 million, a 5.7% gain.
3. The sports medicine, extremities, trauma craniomaxillofacial and thoracic segment saw $562.2 million in sales, a 19.5% increase year over year.
4. Technology and data, bone cement and surgical sales were $171.8 million, a 14.6% increase year over year.
5. U.S. sales were just over $1.2 billion, and international sales were $$877.4 million.
6. The company expects full-year 2026 sales to grow 2.5% to 4.5% year over year.
7. “We are off to a solid start to the year — strategically, operationally and financially,” CEO Ivan Tornos said in a news release. “Our first quarter results reflect healthy end markets, continued momentum from our recently launched products and disciplined execution across the business. Given our progress and with our go-to-market transformation proceeding as planned, we are raising our adjusted EPS guidance and free cash flow expectations for the year. We remain confident that our strategy will position Zimmer Biomet for consistent, durable growth over the longer term.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
